Background: Water avoidance stress (WAS) induces a naloxone-independent vis-
| INTRODUC TI ON
Brain corticotropin-releasing factor (CRF) acts as a central mediator of stress by orchestrating several responses such as endocrine (hypothalamic-pituitary-adrenal axis), behavioral (anxiety and depression-like), 1 autonomic, 2 and visceral. 3 CRF actions are initiated by binding to two subtypes of G-protein-coupled receptors: CRF subtype 1 (CRF 1 ) and to a lesser extent subtype 2 (CRF 2 ). 4 The CRF receptors are expressed in several stress-related brain regions. 5, 6 Stress is also known to modulate pain, inducing hyperalgesia or analgesia depending upon the nature, duration, and magnitude of the stressor. 7, 8 Concerning stress-induced analgesia, in the somatic pain field, a number of studies demonstrated that exogenous CRF can induce analgesia and endogenous CRF signaling in the brain plays a role in acute physical and psychological stress-induced analgesia. [8] [9] [10] [11] [12] [13] This response occurs through the recruitment of endogenous descending inhibitory pain pathways. [8] [9] [10] [11] [12] [13] So far the role of CRF receptor subtype(s) involved has not yet been characterized except in one study indicative of a mediation through CRF 2 receptors.
14 By contrast, to this date, stress-induced visceral analgesia (SIVA) has been understudied. Existing literature in rodents indicates that exposure to a mild psychological stressor such as water avoidance stress (WAS) 15 or intracerebroventricular (ICV) injection of CRF promotes visceral hyperalgesia 16, 17 in rodents. Of note, all those studies were performed using an invasive surgical technique to monitor the visceromotor response (VMR) to colorectal distension (CRD) by chronically implanting electromyographic (EMG) electrodes on the abdominal wall of rodents. Conversely, our recent studies, using a non-invasive method of VMR recording based on manometry, 18, 19 highlighted the development of visceral analgesia in response to acute and/or repeated WAS in both mice and rats. 19, 20 Since then, other groups using WAS paired with CRD as a visceral painful stimulus have reproduced this visceral analgesic response in rats, using similar non-invasive VMR recording 21 or acute fixation of EMG electrodes on the external oblique muscles (30 minutes before CRD). 22 We and others also established that the visceral analgesia induced by acute and repeated WAS is opioid-independent in male rats. 20, 22 Outside of the reported role for brain-neurotensin signaling in rodents, [23] [24] [25] the underlying neurochemical substrata underpinning SIVA are still not well characterized. Of interest, the involvement of brain CRF signaling that contributes to a number of biological responses induced by stress 1 remains largely unexplored in the SIVA response.
Therefore, in the present study, we first assessed the dose-response effect of CRF injected ICV on visceral pain by monitoring the VMR to CRD non-invasively in male rats. We tested several doses based on previous studies in the somatic pain field pointing to a narrow effective dose range. 12 Since previous studies established a brain-to-blood transport of CRF, 26 we injected CRF intraperitoneally to confirm that the ICV injection of CRF-induced SIVA was brain-mediated; then, we characterized the receptor subtypes involved in the effect of centrally injected CRF using the long-acting CRF 1 and CRF 2 antagonist, astressin-B, 27 and the se- 
| MATERIAL AND ME THODS

| Animals
Key Points
• Recent reports indicate that WAS induces a naloxoneindependent visceral analgesia in male rats under noninvasive conditions of monitoring, but the underlying brain mechanisms are still unknown.
• When injected intracerebroventricularly (ICV) at low nanogram range doses, CRF induces a CRF 1 receptor-mediated visceral analgesic response to colorectal distension that is prevented by ICV injection of the oxytocin antagonist. In contrast, acute WAS recruits endogenous CRF 2 and oxytocin receptor signaling to induce SIVA.
• Increasing the understanding of mechanisms by which stress promotes visceral analgesia and how dysfunction of this pathway leads to visceral hyperalgesia may help developing new therapeutic venues for patients with functional gastrointestinal disorders who exhibit abnormal endogenous pain modulation.
| Treatments
| Intracerebroventricular injection
Rats were equipped with a chronic ICV cannula as previously described. 18 The guide cannula (22 On the day of the experiment, rats were briefly anesthetized with isoflurane (3% in O 2 ) and the lubricated "balloon-pressure sensor"
catheter was introduced into the colorectum such that the distal end of the balloon was at 1 cm from the anus, and the catheter was secured to the tail with tape. Rats were placed in an individual
Bollman cage to which they had been habituated for the past 3 18,20
| Data analysis
The phasic component of the intracolonic pressure (pICP) was extracted from the ICP signal recorded by applying the "DC Remove"
Process in Spike 2 with a time constant of 1 second, to exclude the slower, tonic changes in ICP resulting from colonic smooth muscle activity, and by applying the "RMS amplitude" Process with a time constant of 1 second to the resulting trace. The VMR was defined as the increase in area under the curve (AUC) of pICP during CRD over the mean value of pre-and post-distension 20-second periods and was quantified using the "modulus" process in Spike 2.
As each CRD pressure was repeated two times, the values taken before, during, and after CRD were averaged for each pressure. 
| Compounds
The human/rat CRF, astressin-B, and astressin 2 -B (J. Rivier, Peptide
Biology Laboratories, Salk Institute, La Jolla, CA, USA) were stored in powder form at −80°C and diluted in sterile saline (CRF) or water (astressin-B, astressin 2 -B) immediately before use. Tocinoic acid (Sigma-Aldrich, St Louis, MO, USA) was dissolved in saline.
| Experimental protocols
All experiments were performed in the morning, between 8 am and 12 pm each day to avoid variations due to the circadian rhythm.
| Influence of intracerebroventricular vs intraperitoneal injection of CRF on visceral sensitivity to CRD
Groups of rats were equipped with ICV cannula at least one week before the experiments. Rats were injected ICV with saline (5 μL/ rat) and the VMR to a first CRD was monitored 5 minutes later (baseline response). After 1-hour rest period, saline (5 μL/rat) or CRF (10, 30, 100, and 300 ng/rat and 1, 3, and 5 μg/rat in 5 μL) was injected ICV and a second CRD was performed 5 minutes later. In a separate study, naïve rats were used to assess the influence of peripheral administration of CRF. Rats were subjected to first CRD and 1 hour later were injected IP (0.2 mL/rat) with saline or CRF (10 µg/kg, ie, ~3 µg/rat), and 15 minutes later, the second CRD was performed in both groups. The doses of CRF were based on our previous studies showing dose-related (ICV) or maximal effect effects (IP) on gut function. 37, 38 CRF at 300 ng/rat inducing the maximal visceral analgesic effect was selected for all further ICV studies.
| Effect of CRF receptor antagonists on ICV CRF-induced visceral analgesia
In separate groups, ICV cannula-equipped rats had a baseline VMR to first CRD, and after the 1-hour rest period, astressin-B (30 μg/ rat), astressin 2 -B (10 μg/rat), or sterile water (5 μL) was injected ICV 5 minutes before ICV CRF (300 ng/rat, 5 μL) and a second CRD was performed 5 minutes later. The ICV doses of astressin-B and 
| Influence of astressin-B, astressin 2 -B, and tocinoic acid on WAS-induced visceral analgesia
In other groups, after a baseline on day 0, 24 hours later, astressin-B (30 μg/rat), astressin 2 -B (10 μg/rat), tocinoic acid (20 μg/rat), or their respective vehicles (sterile water and saline) were injected ICV in 10 µL, 15 minutes before exposure to WAS for 1 hour. A second CRD was performed within ~45 minutes of the stress ending as previously published. 20 The doses of receptor antagonists used were based on above experiment showing blockade of ICV CRF-induced visceral analgesia.
| Statistical analyses
Statistical analyses were performed using GraphPad Prism ver- 
| RE SULTS
| CRF injected ICV induces visceral analgesia to CRD, while IP CRF induces visceral hyperalgesia
In male rats equipped with a chronic ICV cannula, the ICV injection of saline and, 5 minutes later, a first CRD at 10, 20, 40, and 60 mm Hg induced a stimulus-intensity-related increase in the VMR recorded by intraluminal colonic pressure. This baseline was not modified when the same protocol (ICV saline followed by second CRD) was repeated 1 hour later ( Figure 1A ). By contrast, ICV CRF at 100 and 300 ng/rat resulted in a significant decrease of the VMR at 60 mm Hg CRD compared to baseline (VMR in % control:
63.4% ± 6.8% and 51.3% ± 11.7% vs 100.0% ± 0.0% for 100 and 300 ng/rat, P < 0. 167.7% ± 37.4% (P < 0.001), respectively (Figures 2 and 3A) , while the vehicle (saline) injected IP had no effect ( Figure 3B ).
| Astressin-B induces visceral hyperalgesia and blocks ICV CRF-induced visceral analgesia while astressin 2 -B has no effect
The ICV injection of CRF (300 ng) decreased significantly the VMR to CRD at 60 mm Hg in ICV saline pretreated rats (−5 minutes) compared to baseline values (VMR in % control: 35.0% ± 15.8% vs 100.0% ± 0.0%; Figure 4A ) as we observed in previous experiment in non-ICV pretreated rats. By contrast, in rats pretreated ICV with the CRF antagonist astressin-B, ICV CRF increased significantly the VMR to CRD at both 40 and 60 mmHg compared to baseline (VMR in % control: 116.2% ± 26.0% and 148.1% ± 32.0% vs 64.6% ± 11.5% and 100.0% ± 0.0%, respectively, P < 0.05 each; Figure 4B ). Astressin-B injected ICV plus ICV saline increased the 
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VMR to CRD only at 60 mm Hg compared to baseline (VMR in % control: 155.1% ± 11.0% vs 100.0% ± 0.0%, P < 0.05; Figure 4C ).
The selective CRF 2 antagonist astressin 2 -B injected ICV as pretreatment (−5 minutes) did not influence the analgesic response to ICV CRF as shown by the significant decrease of the VMR to CRD at 60 mm Hg compared to baseline (VMR in % control: 37.1% ± 16.5% vs 100.0% ± 0.0%; Figure 3D ), and the peptide + ICV saline did not influence the VMR to CRD ( Figure 4E ).
| The ICV oxytocin receptor antagonist tocinoic acid induces visceral hyperalgesia and blocks ICV CRF-induced visceral analgesia
The ICV injection of tocinoic acid (20 µg/rat) plus ICV saline increased the VMR to CRD at 40 mm Hg (VMR in % control: 113.4% ± 28.5% vs 45.1% ± 16.6%, P < 0.01) while at 60 mm Hg the response did not reach statistical significance (VMR in % control: 138.7% ± 25.7% vs 100.0% ± 0.0%, P > 0.05; Figure 5A ). The ICV pretreatment with tocinoic acid, abolished the development of visceral analgesia induced by ICV CRF ( Figure 5B ) at 60 mm Hg.
| ICV CRF and oxytocin receptor antagonists block SIVA induced by WAS
We then assessed whether SIVA induced by WAS is modified by blockade of CRF and oxytocin receptors. In rats pretreated with saline, WAS for 1 hour decreased the VMR to CRD at 60 mm Hg by −47.4% ± 14.3% compared with baseline when monitored at the end the stress exposure (VMR in % control: 44.1% ± 13.5% vs 100.0% ± 0.0%, P < 0.0001; Figure 6A ). The ICV injection of F I G U R E 4 Involvement of CRF receptors in ICV CRF-induced visceral analgesia. In male rats chronically implanted with an ICV cannula, a baseline CRD was performed. One hour later, rats received an ICV injection of saline (A), astressin-B (B), or astressin 2 -B (D) followed 5 minutes later by ICV CRF (300 ng/rat) before the second CRD. In other groups, the same protocol was applied except that astressin-B (C) or astressin 2 -B (E) was given 5 minutes before ICV saline. Baseline: white squares, postinjection: black squares. Data are means ± SEM, of number of rats as indicated in parenthesis. *P < 0.05, ***P < 0.001 vs respective baseline, two-way repeated-measures ANOVA and Sidak post hoc test F I G U R E 5 ICV CRF recruits oxytocin to mediate ICV and WAS-induced visceral analgesia. In male rats chronically implanted with an ICV cannula, a first CRD was performed (baseline, white squares), and 1 hour later, groups of rats were injected ICV with tocinoic acid and 15 minutes later with ICV CRF (A) or saline (B) (black squares). In a separate group of animals, on day 0, a baseline CRD was performed. Twenty-four hours later, rats were injected ICV with tocinoic acid (C) and, 15 minutes later, exposed to 1 hour of WAS followed by a second CRD. Data are means ± SEM, n as indicated in parenthesis. *P < 0.05 vs baseline, two-way repeated-measures ANOVA and Sidak post hoc test astressin-B (Figure 6B ), astressin 2 -B ( Figure 6C ), and tocinoic acid ( Figure 5C ) prevented WAS-induced SIVA, and values of VMR were identical to those of baseline after injection of astressin-B and tocinoic acid, but showed a non-significant tendency for hyperalgesia after astressin 2 -B.
| D ISCUSS I ON
The present study showed that ICV injection of CRF induces visceral analgesia in male Sprague-Dawley rats. The ICV injection of CRF at 100 or 300 ng/rat significantly reduced the VMR at 60 mm Hg by −36.6% ± 6.8% and −48.7% ± 11.7%, respectively, from ICV saline control, while the 30 ng/rat dose had no effect. The analgesic response occurred at ICV doses of CRF known to have no effects on locomotor behavior. 43 These data indicate that at a nanogram 16 Strain differences between these studies may have played a role as distinct visceral sensitivity to CRD has been reported previously between Fischer-344 and Wistar rats. 17 In addition, the distinct preconditions of the animals linked to the method used to monitor visceral pain (no abdominal surgery for intracolonic pressure recording of VMR in the present study vs surgical chronic implantation of EMG electrodes may have contributed to these differences as recently reviewed. 45 We previously reported that the surgical intervention and EMG electrodes implanted into the external oblique abdominal muscle then exteriorized in the back of neck modify the visceral pain responses of rodents to WAS when assessed 5 days postsurgery. 19 Indeed, studies in the somatic pain field demonstrated that the assessment of pain is not only the result of nociceptive input level but is also dependent upon the prior stress/nociceptive events that induce a latent pain sensitization switching stress-induced analgesia to hyperalgesia. [45] [46] [47] Under our conditions of testing, we were not able to detect a significant influence of the brain surgery for the chronic implantation of ICV cannula on the visceral pain response of rats. We hypothesize that the lack of sensitization of the visceral pain responses following brain surgery when compared with abdominal and paw surgeries 19,48,49 may be due to different projections and convergence of sensory pathways in the spinal cord.
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We then assessed whether ICV injection of CRF-induced reduction of VMR to CRD was mediated in the brain since previous studies established a brain-to-blood transport of CRF. 26 Two sets of evidence support that the peptide acts in the brain. Firstly, CRF injected IP at ~3 µg/rat results in a significant visceral hyperalgesia to CRD when monitored under similar conditions. These data expand our previous reports showing that IP injection of the CRF 1 agonist cortagine 51 induced a peripherally mediated increase in the VMR to CRD in rats when monitored similarly, as in the present study.
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Secondly, the decreased VMR to CRD is observed only at the lowest doses (100-300 ng/rats), and no longer at the highest (1, 3, or 5 µg/ rat) which should result in a more prominent leakage of the peptide from the cerebrospinal fluid to the peripheral circulation. 26, 52 The latter resulted in hyperalgesia as demonstrated with the IP injection of CRF, and not analgesia. The lack of analgesic effect of ICV at high doses may be due to an increased leakage of the CRF peptide from F I G U R E 6 Involvement of CRF receptors in acute WAS-induced visceral analgesia. On day 0, a baseline CRD was performed, and 24 hours later, rats were injected ICV with saline (A), astressin-B (B), or astressin 2 -B (C) and, 15 minutes later, exposed to 1 hour of WAS followed by a second CRD. Baseline: white squares, postinjection: black squares. Data are means ± SEM, number of rats as indicated in parenthesis. ****P < 0.0001 vs respective baseline, two-way repeatedmeasures ANOVA and Sidak post hoc test antagonist astressin 2 -B injected ICV had no effect against CRF-induced SIVA or under basal conditions. It is unlikely that the lack of antagonist effect of astressin 2 -B is due to a submaximal regimen of administration (10 µg/rat). We previously reported that the injection of astressin 2 -B into the rat cerebrospinal fluid at 3 or 10 µg/rat completely prevented intracisternally injected CRF (300 ng)-or urocortin 2 (100 ng)-induced delayed gastric emptying in rats. 39 73 and may in turn lead to the recruitment of brain circuitries to induce SIVA which differ from the ones recruited by the stimulation of a proximal single pathway using ICV CRF as previously reported for other stressors.
74,75
We next assessed the underlying central mechanisms of SIVA.
Stress and ICV injection of CRF induce the release of neuropeptides such as oxytocin (OT) 29, 76, 77 established to induce analgesic effect in different modalities of acute pain (neuropathic, somatic, or inflammatory) in rodents and humans. 30, 31 Moreover, in rat brain, synaptic connections between OT and CRF containing neurons were identified in the PVN 78 and CRD stimulates the activity of both CRF and OT neurons as shown by the induction of Fos expression and double labeling. 66 Pharmacological and neuroanatomical evidence support the implication of hypothalamic OT in somatic analgesia [79] [80] [81] [82] and a reciprocal regulation of OT and CRF hypothalamic systems in stress response. 83 No study has assessed their implication in SIVA, yet. Interestingly, using an OT receptor antagonist, tocinoic acid, we found that the antagonism of the 
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